FDA Parries on Teva 180-Day Exclusivity Suit

Drug Industry Daily
A A
The FDA hit back at Teva’s lawsuit accusing the agency of changing its policy on granting 180-day exclusivity for generics — arguing that the company’s attempt to block exclusivity for competing Restasis (cyclosporine) generics was “built atop a tottering tower of conjecture.”

To View This Article:

Login

Subscribe To Drug Industry Daily